Sprycel (dasatinib), a new oral drug for certain forms of leukemia

August 2006

There's lots of excitement about Sprycel (dasatinib), a new oral drug for certain forms of leukemia.

It's for patients who are resistant to or can't take other treatments...including Gleevec (imatinib).

Sprycel is a tyrosine kinase inhibitor...similar to Gleevec.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

the risk of jaw bone damage while taking Fosamax or other bisphosphonates
Cardiology reimbursement for Zocor and the new generic simvastatins
Cardiology More patients will be started on a beta-blocker before surgery
Vaccines CDC will soon recommend a booster of the chickenpox vaccine
Vaccines shortage of Menactra (meningococcal vaccine)
Neurology & Pain two new ORAL forms of oxymorphone called Opana and Opana ER
Diabetes New "guidelines" for treating pain due to diabetic peripheral neuropathy
Infectious Diseases several changes in HIV drug therapy
Women's Health new oral contraceptive called Seasonique
Women's Health prenatal vitamins with DHA
treatment options for eating disorders
Hematology & Oncology Sprycel (dasatinib), a new oral drug for certain forms of leukemia
Hematology & Oncology Cesamet (nabilone) is a new option for nausea and vomiting associated with chemotherapy
Smoking Cessation Chantix (varenicline) is the latest option for smoking cessation